The Relationship Between De Ritis Rate and Fatty Liver in Covid-19 Patients

Abstract

Objective: This study aimed to comparatively examine the relationship between the rate of De Ritis and fatty liver in COVID-19 patients. Method: A total of 182 COVID-19 patients, 133 men and 49 women, were included in the study. The study was carried out on patients with a definitive diagnosis of COVID-19 between May 1, 2020 and March 29, 2021. This study is retrospective and the data were obtained from the hospital information management system. The diagnosis of COVID-19 in the included patients was made by a real-time polymerase chain reaction and computed tomography lung scanning. In COVID-19 patients, fatty liver was graded ultrasonographically, and the relationship between the De Ritis rate and the correlation was compared. Results: De Ritis rate was found to be significant between patients with and without COVID-19 infection. De Riti's rate of patients with COVID-19 infection was found to be significantly lower. De Ritis rate was found to be considerably lower in men with COVID-19 infection than in women with COVID-19 infection. When the GRADEs of COVID-19 patients with NAFLD and non-patient groups were compared, no statistical difference was detected. Conclusion: The De Ritis rate was significant between patients with and without COVID-19 infection, and the significantly low De Ritis rate in patients with COVID-19 infection revealed that COVID-19 disease reduced the rate of De Ritis. When the GRADEs of COVID-19 patients with NAFLD were compared with non-patient groups, the lack of statistical difference revealed that COVID-19 infection did not affect the fatty liver.

Keywords

• COVID-19
• nonalcoholic fatty liver disease
• De Ritis

References

1. Ak G. (2020). COVID-19’un Klinik ve Radyolojik Özellikleri. ESTÜDAM Halk Sağlığı Dergisi, 5(COVID-19 Özel Sayısı):61-69.
2. Botros M, Sikaris KA. (2013). The de ritis ratio: The test of time. Clin Biochem Rev, 34:117-30. Çelik D, Köse Ş. (2020). Erişkinlerde COVID-19: Klinik bulgular. Tepecik Eğit. ve Araşt. Hast. Dergisi, 30(Ek sayı):43-48.
3. Çolak Y, Tuncer İ. (2010). Nonalkolik Karaciğer Yağlanması Ve Steatohepatit. İst Tıp Fak Derg, ;73:3:85-91. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C. (2020). Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol, 18(7):1561-1566. doi: 10.1016/j.cgh.2020.04.002.
4. Fu L, Wang B, Yuan T. (2020). Clinical characteristics of coronavirus disease 2019 (COVID 19) In China: A systematic review and meta-analysis. J Infect, 80(6):656-665. doi:10.1016/j.jinf.2020.03.041
5. Gordon DE, Jang GM, Bouhaddou M, Xu J, Oberner K, White KM. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 583;459–468. doi.org/10.1038/s41586-020-2286-9
6. Gorgel SN. (2017). The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy. International Urology and Nephrology, 49(9):1577–1583.
7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Yl. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395;497-506. doi:10.1016/S0140- 6736(20)30183-5
8. Ikeda T. 2020. The De Ritis (aspartate transaminase/alanine transaminase) ratio as a prognosticator in patients with end-stage renal disease-associated renal cell carcinoma. Clinical Genitourinary Cancer, 18(3):236–240.

9. Kwo PY, Cohen SM, Lim JK. (2017). ACG Clinical Guideline: Evaluation of abnormalliver chemistries. Am J Gastroenterol, 112:18-35.
10. Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R. (2020). High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol, 73(3):705-708. doi:10.1016/j.jhep.2020.05.013
11. Nannipieri M, Gonzales C, Baldi S. (2005). Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care, 28:1757-62.
12. Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, et al. (2020). Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. Hepatology, 72(3):807-817. doi: 10.1002/hep.31404.
13. Prati D, Taioli E, Zanella A. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med, 137:1- 10.
14. Portincasa P, Krawczyk M, Machill A, Lammert F, Di Claula A. (2020). Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med, 77:18-24. doi: 10.1016/j. ejim.2020.05.035.
15. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J. (2020). Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4.
16. Singh S, Khan A. (2020). Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. Gastroenterology, 159(2):768-771
17. Xu Z, Shi L, Wang Y. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 8:420–422.
18. Yazar H, Kayacan Y, Özdin M. (2021). Investigation of C-reactive Protein and D-dimer Findings in Patients with COVID-19. Bezmialem Science, 9(Supplement 1):4-8.
19. Yazar H, Kayacan Y, Ozdin M. (2020): De Ritis ratio and biochemical parameters in COVID-19 patients. Archives of Physiology and Biochemistry, 128(6):1676-1680. DOI: 10.1080/13813455.2020.1788604.
20. Zeng-hong W. Dong-liang Y. (2020). A meta-analysis of the impact of COVID-19 on liver dysfunction European Journal of Medical Research, 25(1):54-57.